Drug Profile

MBF 251

Alternative Names: MBF-251

Latest Information Update: 28 Jul 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Medibiofarma
Class Antineoplastics; Benzamides; Phenyl ethers; Small molecules
Mechanism of Action Prostaglandin E EP2 receptor antagonists; Prostaglandin E EP4 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Jul 2021 Discontinued - Preclinical for Cancer in Spain (unspecified route) (Medibiofarma pipeline, July 2021)
28 Jul 2021 Discontinued - Preclinical for Endometriosis in Spain (unspecified route) (Medibiofarma pipeline, July 2021)
26 Mar 2021 Medibiofarma has patents pending worldwide for optionally substituted, N-benzyl-2- phenoxybenzamide derivatives as modulators of EP4 and/or EP2 receptors of prostaglandin E2

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com